BridgeMD
New treatment option for Zoster; Herpes, Trigeminal Neuralgia (Etiology)
Official title Esketamine Combined Pulsed Radiofrequency for Acute/Subacute Zoster-associated Trigeminal Neuralgia
ClinicalTrials.gov ID: NCT06890897
What this study is testing
What is Esketamine group?
Esketamine group is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for zoster; herpes, trigeminal neuralgia (etiology).
Also referred to as Esketamine + PRF+standardized treatment.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- To assess the 1-month effects and safety of esketamine combined PRF and standardized treatment to relieve pain in patients with acute/subacute zoster-related trigeminal neuralgia(ZRTN).
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age \>18 years;
- History of HZ within the last three months;
- Lesions located in the trigeminal nerve or its branches innervated regions；
- Numeric Rating Scale (NRS) pain score≥4 (NRS, 0 = no pain, 10= worst possible pain) with pharmacotherapy;
- Planned to perform CT-guided PRF treatment of the Gasserian ganglion .
You likely can't join if
- Obstructive sleep apnoea syndrome;
- Those who receive other invasive treatments, such as spinal cord stimulation;
- A history of systemic immune diseases, organ transplantation, or cancers;
- A history of severe cardiopulmonary, hepatic or renal dysfunction;
- A history of schizophrenia, epilepsy, or myasthenia gravis, delirium;
- Comorbid hyperthyroidism or phaeochromocytoma;
See the full eligibility criteria
- Age \>18 years;
- History of HZ within the last three months;
- Lesions located in the trigeminal nerve or its branches innervated regions；
- Numeric Rating Scale (NRS) pain score≥4 (NRS, 0 = no pain, 10= worst possible pain) with pharmacotherapy;
- Planned to perform CT-guided PRF treatment of the Gasserian ganglion .
- Obstructive sleep apnoea syndrome;
- Those who receive other invasive treatments, such as spinal cord stimulation;
- A history of systemic immune diseases, organ transplantation, or cancers;
- A history of severe cardiopulmonary, hepatic or renal dysfunction;
- A history of schizophrenia, epilepsy, or myasthenia gravis, delirium;
- Comorbid hyperthyroidism or phaeochromocytoma;
- Recent history of drug abuse;
- Having contraindications to esketamine;
- Communication difficulties. Withdrawal criteria
- Lost to follow-up during the study;
- Not perform the planned operation;
- Receiving other treatment regimes during the study period;
- Not suitable for continuing the study for emerging severe comorbidities or special physiological changes during the study;
- Voluntary withdrawal from the study.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.